DoW Multiple Sclerosis Clinical Trial Award
This grant funds clinical trials testing new treatments, drugs, devices, or technologies for multiple sclerosis, offering support for both small pilot studies and larger phase 1 or 2 trials with required preliminary data.
Funder: Dept. of the Army -- USAMRAA
Due Dates: July 30, 2026 (Pre-Application/LOI) | August 13, 2026 (Full application) | August 20, 2026 (Application verification)
Funding Amounts: ~$4,000,000 total; up to $1M (3 yrs, FL1) or $2M (4 yrs, FL2) per award; ~3 awards expected
Summary: Supports rapid implementation of clinical trials with significant potential impact on the treatment or management of multiple sclerosis.
Key Information: Open to domestic and foreign, for-profit and nonprofit organizations; only one application per PI allowed.
Description
This opportunity supports the rapid execution of clinical trials that address significant gaps in the treatment or management of multiple sclerosis (MS). The program is part of the Congressionally Directed Medical Research Programs (CDMRP) and aims to fund both small-scale, proof-of-principle trials as well as larger phase 1 or 2 trials. Projects must address one or both of the following focus areas: (1) promoting repair, neuroprotection, and remyelination in MS, or (2) treatment of MS symptoms. Both new and established investigators are encouraged to apply, and multidisciplinary collaborations are welcomed.
